Top 25 Life Science Startup Investors in Norway (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Investinor
VC Fund
|
3 | Norway, United States, Sweden | Series A, Seed | Software, Biotechnology, Manufacturing | $400k–$25M |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Canica
VC Fund
|
2 | Norway, Denmark, Singapore | Private Equity, Series A, Venture - Series Unknown | Biotechnology, Beauty, Retail | $7M–$29M |
|
Sandwater
VC Fund
|
2 | Norway, Germany, France | Series A, Seed | AgTech, Medical, Agriculture | $8.5M–$24M |
|
ERM Invest
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Silverline Capital
VC Fund
|
1 | Bulgaria, Norway, United States | Venture - Series Unknown, Series A | Machine Learning, Artificial Intelligence, Retail | $2.8M–$27M |
|
Project Sandwater
VC Fund
|
1 | Norway, The Netherlands | Series A | Medical, Consulting, Life Science | $12M–$20M |
|
Birk Venture
VC Fund
|
1 | Norway, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $1.2M–$20M |
|
Qomel
VC Fund
|
1 | Norway | Seed | Life Science, Biotechnology | |
|
Nordic Impact
VC Fund
|
1 | Norway | Seed | Chemical, Life Science, Visual Search | |
|
Sofinnova Partners
VC Fund
|
1 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Lekh Corp AS
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Wa’ed Ventures
VC Fund
|
1 | Saudi Arabia, United Arab Emirates, United States | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $500k–$124M |
|
Arkin Bio Ventures
VC Fund
|
1 | United States, Israel, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$182M |
|
World Wildlife Fund
VC Fund
|
1 | Canada, Norway, Faroe Islands | Seed, Series A | Seafood, Aquaculture, Food Processing | $1.9M–$6.2M |
|
Bioqube Ventures
VC Fund
|
1 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
H2O Holding AS
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Hadean Ventures
VC Fund
|
1 | Norway, Sweden, Austria | Series A, Series B | Biotechnology, Health Care, Medical | $4.3M–$79M |
|
NantBio
VC Fund
|
1 | Norway | Seed | Life Science, Biotechnology | |
|
4BIO Capital
VC Fund
|
1 | United States, United Kingdom, France | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $5M–$125M |
|
The Index Project
VC Fund
|
1 | United States, Denmark, Chile | Seed, Series A, Series B | Chemical, Artificial Intelligence, SaaS | $1.1M–$3M |
|
Dynamk Capital
VC Fund
|
1 | United States, Canada, Norway | Series A, Seed, Series B | Biotechnology, Medical, Health Care | |
|
Surveyor Capital
VC Fund
|
1 | United States, China, Canada | Series B, Post-IPO Equity, Series C | Biotechnology, Health Care, Therapeutics | $41M–$280M |
|
Bakken & Baeck
VC Fund
|
1 | Norway | Seed, Angel | Chemical, Software, Life Science | |
|
Innovestor
VC Fund
|
1 | Finland, Sweden, Denmark | Seed, Pre-Seed | Software, Health Care, Information Technology | $204k–$4.5M |
| Access all 42 investors in Norway Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Series A, Seed
- Geography: Norway, United States, Sweden
Investor stats
- Total investments: 123
- Round size: Seed $400k–$3.6M; Series A $2M–$25M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $148M in 2011
Portfolio highlights
- Sonair — Make your robot safe, affordable, and efficient with the Sonair 3D ultrasonic sensor.
- Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
- Muybridge — Reimagining cameras with weightless software-based viewpoint
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 174
- Round size: Seed $2.4M–$24M; Series A $5.6M–$50M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- ApoGen Biotechnologies — Explore fast payout casinos that deliver winnings instantly or under 24 hours. List of the best payout casinos to get same day winnings.
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more...Investment focus
- Industry: Biotechnology, Beauty, Retail
- Stage:Private Equity, Series A, Venture - Series Unknown
- Geography: Norway, Denmark, Singapore
Investor stats
- Total investments: 14
- Round size: Series A $7M–$25M; Venture - Series Unknown $20M–$29M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Healthily — The path to perfect health starts with self-care and Healthily is here to guide you step by step.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Oncoinvent — Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns.
We are Sandwater. Regeneration of our resources. Vitalizing healthcare & education. Improving life through technology.
Show more...Investment focus
- Industry: AgTech, Medical, Agriculture
- Stage:Series A, Seed
- Geography: Norway, Germany, France
Investor stats
- Total investments: 24
- Round size: Series A $8.5M–$24M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Mantle8 — Using bottom-up exploration and decades of geology experience, we are on a mission to deliver natural hydrogen to the world.
- CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
- Alva Industries — Serving industries from aerospace to marine, we deliver high-performance, sustainable motors to drive a cleaner, more efficient future.
Investment Company
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aurora Analytica — Clinical intelligence built human-first: rule-based decision engines with trusted, auditable AI. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.
Silverline Capital provides mezzanine and equity financing solutions to mid-market businesses in Bulgaria.
Show more...Investment focus
- Industry: Machine Learning, Artificial Intelligence, Retail
- Stage:Venture - Series Unknown, Series A
- Geography: Bulgaria, Norway, United States
Investor stats
- Total investments: 6
- Round size: Series A $8.3M–$27M; Venture - Series Unknown $2.8M–$3.5M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications
- Evrotrust — Best way to prove who you are and agree to anything, anywhere. Fully legal, secure and personal. Our mobile first eIDAS solution allows: eID, eSign, eTimestamp, eSeal, eDelivery with the highest status – qualified
- Codery — Codery functions as an Employer of Record (EOR), acting as the official employer for hired professionals. The firm handles the administrative and legal parts of employment, such as registration, payroll, and compliance with local labor laws, allowing enterprises to hire without having to establish regional offices or legal entities.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more...Investment focus
- Industry: Medical, Consulting, Life Science
- Stage:Series A
- Geography: Norway, The Netherlands
Investor stats
- Total investments: 2
- Round size: Series A $12M–$20M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Norway, United Kingdom
Investor stats
- Total investments: 9
- Round size: Seed $1.3M–$15M; Series A $1.2M–$20M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity. It is the first company to have engineered a viral point of entry to cancer cells while bypassing healthy cells - so it’s ‘gloves off’ in the fight against cancer." It was founded in 2020 and is locatedin Oxford, Oxfordshire, United Kingdom.
Qomel Company is a healthcare and pharmaceutical services company that offers medical, diagnostic, and product distribution services. It operates ophthalmology, dental, wound care, and general medical services, while distributing pharmaceuticals and medical devices through warehouses and sales offices.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.
Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.
Show more...Investment focus
- Industry: Chemical, Life Science, Visual Search
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 329
- Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Investment Company
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Aurora Analytica — Clinical intelligence built human-first: rule-based decision engines with trusted, auditable AI. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.
Wa’ed Ventures is a $500 million venture capital fund with the aim to accelerate the development of an integrated startup ecosystem by investing in local tech-based startups and incentivizing global entrepreneurs to localize their tech innovations in the Kingdom.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: Saudi Arabia, United Arab Emirates, United States
Investor stats
- Total investments: 120
- Round size: Seed $500k–$5.5M; Series A $2.5M–$30M; Series B $19M–$124M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Terraxy — Terraxy is a startup company building permanent fertile soils to enable greening and agriculture in the desert.
- THINK-AI — Complete in-house freedom to innovate, develop, fine-tune and train AI models for any unique business needs. Own the AI.
- Stake — Thousands investors worldwide use Stake to access income-generating real estate deals in high-growth markets, starting from just USD 136
Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 24
- Round size: Series A $11M–$125M; Series B $13M–$80M; Series C $19M–$182M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Ambros Therapeutics — Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases.
- Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.
Show more...Investment focus
- Industry: Seafood, Aquaculture, Food Processing
- Stage:Seed, Series A
- Geography: Canada, Norway, Faroe Islands
Investor stats
- Total investments: 10
- Round size: Seed $1.9M–$4.7M; Series A $2.9M–$6.2M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- SeaForester — Restoring the forgotten forests in our ocean.
- Cascadia Seaweed — Powered by the Sea. Proven on the Farm. Explore Cascadia Seaweed's portfolio of regenerative solutions, from kelp-based agricultural biostimulants to AI-powered biodiversity monitoring with OceanNexus. Through Cascadia Seaweed and Cascadia Nature-based Solutions, we're helping build healthier farms
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$24M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Investment
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aurora Analytica — Clinical intelligence built human-first: rule-based decision engines with trusted, auditable AI. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Norway, Sweden, Austria
Investor stats
- Total investments: 32
- Round size: Series A $4.3M–$79M; Series B $4.5M–$75M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $105M in 2021
Portfolio highlights
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
NantBio offers treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 32
- Round size: Seed $5M–$19M; Series A $24M–$94M; Series B $12M–$125M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $50M in 2019
Portfolio highlights
- SparingVision — We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of
- Cytospire Therapeutics — Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?
Show more...Investment focus
- Industry: Chemical, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Chile
Investor stats
- Total investments: 9
- Round size: Seed $1.5M–$2M; Series A $1.1M–$3M
- Lead/follow: 0% lead, 100% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Agribuddy — Management of agricultural support application "AGRIBUDDY".
- CanopyLAB — CanopyLAB is an educational technology company located in Hvidovre, Greater Copenhagen, Denmark. We have built an AI-powered social learning platform for corporate training. Through personalization our platform enables all learners to realize their potential in a way that is fast, fun and future-proof. We call it "The Future of Learning-Delivered Today".We work on two verticals:1. The Canopy A social learning platform powered by AI A research-based social learning platform for developing competencies through individualized and adaptive learning experiences. It is designed with an integrated social network structure to enhance collaborative learning and built on strong Nordic learning principles.2. The LAB A learning community with provocative content Join our global learning community for youth. Take free courses, exchange ideas, gain new knowledge and practice competencies offered by 100 + pioneering NGOs in controversial and often neglected topics such as sexuality, sexual & reproductive rights, climate action, health, and the SDGs.CanopyLAB acquired Peruvian publishing startup Yopublico in April 2020.
- Destácame — Destacame is the first behavior-based credit score in Latin America.
Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Norway
Investor stats
- Total investments: 20
- Lead/follow: no public data
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
- Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series C
- Geography: United States, China, Canada
Investor stats
- Total investments: 170
- Round size: Series B $60M–$170M; Series C $60M–$226M; Post-IPO Equity $41M–$280M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Sol-Gel Technologies — Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
- Perspective Therapeutics — Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them.
Since 2011, we have built products with some of the most ambitious companies out there. From defining the future of conversational AI with Sierra to building decentralised platforms with Coinbase.
Show more...Investment focus
- Industry: Chemical, Software, Life Science
- Stage:Seed, Angel
- Geography: Norway
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
- Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications
Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Finland, Sweden, Denmark
Investor stats
- Total investments: 89
- Round size: Seed $478k–$4.5M; Pre-Seed $204k–$2M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — raised $35M in 2020
Portfolio highlights
- Retailgrid — Agentic AI pricing platform for mid-market retailers. Turn messy retail data into structured, explainable price decisions in days, not months.
- Bahn Express — Euroopan nopein autojen kuljetus. Autoliikkeille, autokauppiaille ja kalustonhallintaan. Euroopan halki 72 tunnissa.
- Cornea Sense — CorneaSense is a medtech startup developing a non-invasive, eye-based sensing device that measures ocular surface hydration to enable early detection and monitoring of conditions such as dry eye disease and systemic health disorders. The technology aims to provide real-time, objective eye biomarkers for improved clinical diagnosis and patient care.
Life Science Investor funding in Norway at a glance
Stats across 29 deals from 42 investors.
Access all 42 investors in Norway Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Norway investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 42 investors investing in Norway Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!